New York Harm Reduction Educators
New York, 10035, United States
NCT Number: NCT03226873
This pilot study will assess the feasibility and acceptability of a peer outreach and navigation intervention designed to increase access and promote HIV pre-exposure prophylaxis (PrEP) uptake among women at high risk for HIV.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
New York, 10035, United States
Women who engage in exchange sex (i.e., sex in exchange for money, drugs, or other services) remain are at substantial risk for HIV infection. (1-6) Due to a confluence of social and structural factors, exchange sex is relatively prevalent among women from socially and economically marginalized groups, such as women who are transgender, unstably housed/homeless and/or those who use and/or inject drugs. (1-3, 19-23) The overarching goal of this research is to decrease new HIV infections among women who engage in exchange sex. Daily oral HIV pre-exposure prophylaxis (PrEP) is an innovative method of HIV prevention that women, themselves, can control; as such, PrEP has the potential to reduce the risk of HIV acquisition among women who engage in exchange sex. Therefore, the investigators developed a theory-guided behavioral intervention (PrEP-UP) which utilizes street-based peer outreach and navigation to increase access to PrEP and promote PrEP uptake among women involved in exchange sex. Specifically, PrEP-UP involves a Peer delivering PrEP education and counseling during street-based outreach followed by offer of a PrEP care appointment along with peer navigation (e.g., appointment accompaniment and reminders, etc.) for the first several PrEP care visits. The objective of this study is to assess the feasibility and acceptability of PrEP-UP. To implement PrEP-UP, the investigators will collaborate with an established community-based organization (CBO) in East Harlem, NY, which uses street-based peer outreach and navigation to connect individuals to needed health and social services. Medical and pharmacy records will be reviewed to assess PrEP initiation. The investigators will conduct self-report surveys at baseline and at a week 4-12 follow-up visit that will collect data about sexual and drug use risk behaviors, perceived HIV risk, and PrEP-related knowledge, attitudes, and self-efficacy to assess for temporal changes in these variables. Additionally, individual interviews will be conducted post-intervention with a subset of the women as well as the CBO staff and leadership to access acceptability of the intervention.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Peer education, counseling, and facilitation of PrEP care
Time frame: 4-12 weeks
Obtained from medical and/or pharmacy records
Time frame: week 0, 4-12
Revised Risk Behavior Assessment (Wechsberg)
Time frame: week 0, 4-12
Perceived HIV Risk Scale (Napper)
Time frame: week 0
PrEP Acceptability Scale (Marcus)
Time frame: week 0
PrEP appointment acceptance (yes/ no)
Time frame: week 0-12
Scheduled PrEP appointment (yes/ no)
Time frame: week 0-12
PrEP appointment attendance (yes/ no)
Time frame: week 0, 4-12
PrEP Knowledge Scale (Rucinski) (Kalichman) (Kalichman) (Whiteside)
Time frame: week 0, 4-12
Attitudes Towards PrEP Measurements (Golub) (Holt) (Mimiaga) (Tobias)
Time frame: week 0, 4-12
PrEP Self-Efficacy Scale (adapted from HIV-ASES) (Johnson)
Montefiore Medical Center
Other
Assessing the Feasibility and Acceptability of a Peer Outreach and Navigation Intervention to Increase Pre-exposure Prophylaxis Uptake Among Women at High Risk for HIV
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05664490
Behavior, Behavioral Symptoms
Johannesburg, Gauteng, South Africa
View Trial DetailsNCT06274060
Blood-Borne Infections, Communicable Diseases
Pietermaritzburg, KwaZulu-Natal, South Africa
View Trial DetailsNCT04222504
Behavior, Communicable Diseases
Durban, South Africa
View Trial DetailsNCT05243030
Pre-exposure Prophylaxis
Bangkok, Thailand
View Trial Details